Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.…
Cerenome (CNSY) Q3 2026 Earnings Call Transcript
Cerenome (NASDAQ: CNSY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 28 employees.
The shares were at 0.6301 USD on 20 November 2026, down 95.6% over 52 weeks. Its 52-week range is 0.4287 USD to 19.00 USD: the price is 96.7% below the high and 47.0% above the low.
Its market capitalisation is 6.16M USD.
Cerenome reports revenue down 48.3% year over year.
It holds more cash than debt, a net cash position of 990.00K USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.